Levetiracetam Zentiva (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A. This binding modulates neurotransmitter release, stabilizing synaptic activity and decreasing neuronal hyper‑excitability, which in turn reduces the likelihood of seizure generation and propagation.

The dosage of Levetiracetam Zentiva is individualized. A qualified prescriber determines the appropriate starting dose and any subsequent adjustments based on the patient’s age, renal function, seizure type, and clinical response. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for levetiracetam in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Clinicians must weigh the potential benefits for seizure control against possible risks to the fetus or infant, and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levetiracetam differs from many traditional antiepileptics such as carbamazepine or valproate because it has a distinct mechanism (SV2A binding) and a relatively low potential for drug‑drug interactions. It is often chosen for its favorable tolerability profile, but individual response and side‑effect considerations guide the final therapeutic choice.

Levetiracetam Zentiva tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and avoid exposure to extreme temperatures to maintain potency throughout its shelf life.

Levetiracetam Zentiva is taken orally. Tablets are swallowed whole with water and may be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablets unless specifically instructed.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, blood dyscrasias (e.g., neutropenia), and rare cases of hepatic failure. Immediate medical attention is required if any of these symptoms appear.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment who cannot tolerate dose adjustments, and for pregnant or breastfeeding women when the benefits do not clearly outweigh potential risks.